Babesiosis is an emerging tick-borne disease caused by apicomplexan parasites of the
genus Babesia. With its increasing incidence worldwide and the risk of human-to-human …

Introduction There are 12 protozoan genera that provoke zoonotic disease in humans and
animals. We discuss the most common ones with a highlight on Babesia spp and …

Human babesiosis is a potentially fatal tick-borne disease caused by intraerythrocytic
Babesia parasites. The emergence of resistance to recommended therapies highlights the …

Tafenoquine is a highly effective treatment for Babesia microti infections in animal models.
An immunocompromised patient infected by a strain of B. microti that was at least partially …

Due to drug resistance, commonly used anti-Babesia drugs have limited efficacy against
babesiosis and inflict severe side effects. Tafenoquine (TAF) was approved by the US Food …

Human babesiosis is a CDC reportable disease in the United States and is recognized as
an emerging health risk in multiple parts of the world. The current treatment for human …

To the editor—We read with great interest the study conducted by Vydyam et al entitled
“Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile …

Babesia spp. are intraerythrocytic apicomplexans that digest and utilize red blood cells in a
similar way to intraerythrocytic Plasmodium spp., but unlike the latter, are not sensitive to …

The significant rise in the number of tick-borne diseases represents a major threat to public
health worldwide. One such emerging disease is human babesiosis, which is caused by …

Although tafenoquine was highly effective for eliminating microscopically detectable
parasitemia in mouse models of Babesia microti infection, all of the mice which were …